Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 Mice

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5803-5815

  Meng, Tao ^a   Kwang, Jimmy ^a,b  

^a Animal Health Biotechnology   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CRYSTAL STRUCTURE; ENTEROVIRUS 71; GENETIC VARIABILITY; GENOTYPE; GUANIDINE RESISTANCE ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUTATION RATE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGENY; REVERSE GENETICS; VIROGENESIS; VIRUS ATTENUATION; VIRUS IDENTIFICATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; LETHAL DOSE 50; MICE; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION, MISSENSE; PROTEIN CONFORMATION; RIBAVIRIN; RNA REPLICASE; SERIAL PASSAGE; SURVIVAL ANALYSIS; VIRULENCE;

EID: 84899079298     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00289-14     Document Type: Article

References (49)

1. Domingo E, Sabo D, Taniguchi T, Weissmann C. 1978. Nucleotide sequence heterogeneity of an RNA phage population. Cell 13:735-744. http://dx.doi.org/10.1016/0092-8674(78)90223-4.
2. Eggers HJ, Tamm I. 1965. Coxsackie A9 virus: mutation from drug dependence to drug independence. Science 148:97-98. http://dx.doi.org /10.1126/science.148.3666.97.
3. Domingo E, Wain-Hobson S. 2009. The 30th anniversary of quasispecies. Meeting on "Quasispecies: past, present and future."EMBORep. 10:444-448. http://dx.doi.org/10.1038/embor.2009.61.
4. Domingo E, Holland JJ. 1997. A virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178. http://dx.doi.org/10.1146/annurev .micro.51.1.151.
5. Drake JW, Charlesworth B, Charlesworth D, Crow JF. 1998. Rates of spontaneous mutation. Genetics 148:1667-1686.
6. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. 2000. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379. http://dx.doi.org /10.1038/82191.
7. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895-6900. http://dx.doi.org/10.1073/pnas.111085598.
8. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289-7294. http://dx.doi.org/10.1073/pnas.1232294100.
9. Levi LI, Gnädig NF, Beaucourt S, McPherson MJ, Baron B, Arnold JJ, Vignuzzi M. 2010. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog. 6:e1001163. http://dx.doi.org/10.1371/journal.ppat.1001163.
10. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc. Natl. Acad. Sci. U. S. A. 108:16038-16043. http://dx.doi.org/10.1073/pnas .1111650108.
11. Pfeiffer JK, Kirkegaard K. 2005. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 1:e11. http://dx.doi.org/10.1371/journal.ppat.0010011.
12. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348. http://dx.doi.org/10 .1038/nature04388.
13. Vignuzzi M, Wendt E, Andino R. 2008. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14:154-161. http: //dx.doi.org/10.1038/nm1726.
14. Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129:304-309. http://dx.doi.org/10.1093/infdis/129.3.304.
15. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10:778-790. http://dx.doi.org/10.1016/S1473-3099 (10)70194-8.
16. Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, Takebe Y, Pybus OG. 2010. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 84:3339-3350. http://dx.doi.org/10.1128/JVI .01019-09.
17. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. 1999. Neurologic complications in children with enterovirus infection. N. Engl. J. Med. 341:936-942. http://dx.doi.org/10.1056/NEJM199909233411302.
18. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis and management of human enterovirus 71 infection. Lancet Neurol. 9:1097-1105. http://dx.doi.org/10.1016/S1474 -4422(10)70209-X.
19. Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang J. 2013. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum. Vaccin Immunother. 9:1701-1705. http://dx.doi.org/10.4161/hv.24949.
20. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024-2032. http://dx.doi.org/10.1016/S0140-6736(13)61049-1.
21. Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, Yao X, Miao X, Wu X, Li RC, Wang JZ, Yin WD. 2014. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 (EV71) vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 209:46-55. http://dx.doi .org/10.1093/infdis/jit429.
22. Sutter RW, Cochi SL, Melnick JL. 1999. Live-attenuated poliovirus vaccine. Saunders, Philadelphia, PA.
23. Zinkernagel RM. 2003. On natural and artificial vaccinations. Annu. Rev. Immunol. 21:515-546. http://dx.doi.org/10.1146/annurev.immunol.21 .120601.141045.
24. Lambert PH, Liu M, Siegrist CA. 2005. Can. successful vaccines teach us how to induce efficient protective immune responses? Nat. Med. 11(4 Suppl):S54 -S62. http://dx.doi.org/10.1038/nm1216.
25. Salerno-Gonçalves R, Sztein MB. 2006. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol. 14:536-542. http: //dx.doi.org/10.1016/j.tim.2006.10.004.
26. Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY. 2004. A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 85:69-77. http://dx.doi.org/10.1099/vir.0.19423-0.
27. Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. 2008. The molecular basis of mouse adaptation by human enterovirus 71. J. Gen. Virol. 89:1622-1632. http://dx.doi.org/10.1099/vir.0.83676-0.
28. Wang W, Duo J, Liu J, Ma C, Zhang Wei L Q, Qin C. 2011. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 13:862-870. http://dx.doi.org/10.1016/j.micinf.2011.04 .004.
29. Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 82:1787-1797. http://dx.doi.org/10.1128/JVI.01798-07.
30. Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86:2121-2131. http://dx.doi.org/10.1128/JVI .06103-11.
31. Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, Chitra E, Tsou YL, Chang HW, Sia C, Chong P, Chow YH. 2013. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 8:e57591. http://dx.doi.org/10.1371/journal.pone.0057591.
32. Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, Koike S. 2013. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc. Natl. Acad. Sci. U. S. A. 110:14753-14758. http://dx.doi.org/10.1073/pnas.1217563110.
33. Sadeghipour S, Bek EJ, McMinn PC. 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87:1759-1769. http://dx.doi.org/10 .1128/JVI.02139-12.
34. Sadeghipour S, McMinn PC. 2013. A study of the virulence in mice of high copying fidelity variants of human enterovirus 71. Virus Res. 176: 265-272. http://dx.doi.org/10.1016/j.virusres.2013.06.019.
35. Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J. 2011. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One 6:e21757. http://dx .doi.org/10.1371/journal.pone.0021757.
36. Wu Y, Lou Z, Miao Y, Yu Y, Dong H, Peng W, Bartlam M, Li X, Rao Z. 2010. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-footand-mouth disease pandemic in China. Protein Cell 1:491-500. http://dx .doi.org/10.1007/s13238-010-0061-7.
37. Meng T, Kiener TK, Kwang J. 2012. RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol. J. 9:238-245. http://dx.doi.org/10.1186/1743-422X-9-238.
38. Sadeghipour S, Bek EJ, McMinn PC. 2012. Selection and characterisation of guanidine resistant mutants of human enterovirus 71. Virus Res. 169: 72-79. http://dx.doi.org/10.1016/j.virusres.2012.07.005.
39. Sierra M, Airaksinen A, González-López C, Agudo R, Arias A, Domingo E. 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81:2012-2024. http://dx.doi.org/10.1128/JVI.01606-06.
40. Thompson AA, Peersen OB. 2004. Structural basis for proteolysisdependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J. 23:3462-3471. http://dx.doi.org/10.1038/sj.emboj.7600357.
41. Arnold JJ, Vignuzzi M, Stone JK, Andino Cameron R CE. 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280:25706-25716. http://dx.doi.org/10 .1074/jbc.M503444200.
42. Gnädig NF, Beaucourt S, Campagnola G, Bordería AV, Sanz-Ramos M, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc. Natl. Acad. Sci. U. S. A. 109:E2294-E2303. http://dx.doi.org/10.1073/pnas.1204022109.
43. Lu Z, Asher DM, Levenbook IS, Chumakov KM. 1996. Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys. Virology 220:285-289. http://dx.doi.org/10 .1006/viro.1996.0316.
44. Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, Margolis LB. 1998. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat. Med. 4:346-349. http://dx.doi .org/10.1038/nm0398-346.
45. Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, van Belle S, Turin L, Zdobnov E, Kaiser L, Tapparel C. 2012. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog. 8:e1002826. http://dx.doi .org/10.1371/journal.ppat.1002826.
46. Guan D, van der Sanden S, Zeng H, Li W, Zheng Ma H C, Su J, Liu Z, Guo X, Zhang X, Liu L, Koopmans M, Ke C. 2012. Population dynamics and genetic diversity of C4 strains of human enterovirus 71 in Mainland China, 1998-2010. PLoS One 7:e44386. http://dx.doi.org/10.1371 /journal.pone.0044386.
47. Perales C, Iranzo J, Manrubia SC, Domingo E. 2012. The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol. 20: 595-603. http://dx.doi.org/10.1016/j.tim.2012.08.010.
48. Gutiérrez S, Michalakis Y, Blanc S. 2012. Virus population bottlenecks during within-host progression and host-to-host transmission. Curr. Opin. Virol. 2:546 -555. http://dx.doi.org/10.1016/j.coviro.2012 .08.001.
49. Liu L, Zhao H, Zhang Y, Wang J, Che Dong Y C, Zhang X, Na R, Shi H, Jiang L, Wang L, Xie Z, Cui P, Xiong X, Liao Y, Zhao S, Gao J, Tang D, Li Q. 2011. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 412:91-100. http://dx .doi.org/10.1016/j.virol.2010.12.058.